U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
Go back to U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 80,756 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 80,756 | |||||
